Trial Review

Did you know?

The ANZCTR now automatically displays published trial results and simplifies the addition of trial documents such as unpublished protocols and statistical analysis plans.

These enhancements will offer a more comprehensive view of trials, regardless of whether their results are positive, negative, or inconclusive.

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this information for consumers
Trial details imported from ClinicalTrials.gov

For full trial details, please see the original record at https://clinicaltrials.gov/study/NCT02586909




Registration number
NCT02586909
Ethics application status
Date submitted
23/10/2015
Date registered
27/10/2015
Date last updated
17/04/2020

Titles & IDs
Public title
12-Month Open-Label Extension Study of Intepirdine (RVT-101) in Subjects With Alzheimer's Disease: MINDSET Extension
Scientific title
A Long-Term, Open-Label Extension Study of the Safety and Tolerability of RVT-101 in Subjects With Alzheimer's Disease
Secondary ID [1] 0 0
RVT-101-3002
Universal Trial Number (UTN)
Trial acronym
Linked study record

Health condition
Health condition(s) or problem(s) studied:
Alzheimer's Disease 0 0
Condition category
Condition code
Neurological 0 0 0 0
Alzheimer's disease
Neurological 0 0 0 0
Dementias

Intervention/exposure
Study type
Interventional
Description of intervention(s) / exposure
Treatment: Drugs - RVT-101 35 mg tablets

Experimental: RVT-101 35 mg tablets - once daily, oral tablets


Treatment: Drugs: RVT-101 35 mg tablets
once daily, oral tablets
Intervention code [1] 0 0
Treatment: Drugs
Comparator / control treatment
Control group

Outcomes
Primary outcome [1] 0 0
Occurrence of Adverse Events (AEs) and or Reported Changes in Physical Examinations, Vital Signs Measurements, Electrocardiograms (ECGs), Routine Laboratory Assessments
Timepoint [1] 0 0
Baseline to 12 months or Early Termination

Eligibility
Key inclusion criteria
* Completed last on-treatment visit of the lead-in study RVT-101-3001
Minimum age
50 Years
Maximum age
86 Years
Sex
Both males and females
Can healthy volunteers participate?
No
Key exclusion criteria
* Any clinically relevant concomitant disease, which, in the opinion of the investigator, makes the subject unsuitable for inclusion in the study.

Study design
Purpose of the study
Treatment
Allocation to intervention
Not applicable
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Masking / blinding
Open (masking not used)
Who is / are masked / blinded?



Intervention assignment
Single group
Other design features
Phase
Phase 3
Type of endpoint/s
Statistical methods / analysis

Recruitment
Recruitment status
Stopped early
Data analysis
Reason for early stopping/withdrawal
Other reasons
Date of first participant enrolment
Anticipated
Actual
26/04/2016
Date of last participant enrolment
Anticipated
Actual
Date of last data collection
Anticipated
Actual
12/03/2018
Sample size
Target
Accrual to date
Final
1099
Recruitment in Australia
Recruitment state(s)
Recruitment hospital [1] 0 0
AU227 - Caulfield
Recruitment hospital [2] 0 0
AU032 - Heidelberg West
Recruitment hospital [3] 0 0
AU011 - Hornsby
Recruitment hospital [4] 0 0
AU138 - West Perth
Recruitment postcode(s) [1] 0 0
VIC 3162 - Caulfield
Recruitment postcode(s) [2] 0 0
VIC 3081 - Heidelberg West
Recruitment postcode(s) [3] 0 0
NSW 2077 - Hornsby
Recruitment postcode(s) [4] 0 0
WA 6005 - West Perth
Recruitment outside Australia
Country [1] 0 0
United States of America
State/province [1] 0 0
Arizona
Country [2] 0 0
United States of America
State/province [2] 0 0
California
Country [3] 0 0
United States of America
State/province [3] 0 0
Connecticut
Country [4] 0 0
United States of America
State/province [4] 0 0
Florida
Country [5] 0 0
United States of America
State/province [5] 0 0
Georgia
Country [6] 0 0
United States of America
State/province [6] 0 0
Louisiana
Country [7] 0 0
United States of America
State/province [7] 0 0
Massachusetts
Country [8] 0 0
United States of America
State/province [8] 0 0
Mississippi
Country [9] 0 0
United States of America
State/province [9] 0 0
Nevada
Country [10] 0 0
United States of America
State/province [10] 0 0
New Jersey
Country [11] 0 0
United States of America
State/province [11] 0 0
New York
Country [12] 0 0
United States of America
State/province [12] 0 0
North Carolina
Country [13] 0 0
United States of America
State/province [13] 0 0
Ohio
Country [14] 0 0
United States of America
State/province [14] 0 0
Oregon
Country [15] 0 0
United States of America
State/province [15] 0 0
Pennsylvania
Country [16] 0 0
United States of America
State/province [16] 0 0
Texas
Country [17] 0 0
United States of America
State/province [17] 0 0
Utah
Country [18] 0 0
United States of America
State/province [18] 0 0
Virginia
Country [19] 0 0
United States of America
State/province [19] 0 0
Washington
Country [20] 0 0
Argentina
State/province [20] 0 0
Buenos Aires
Country [21] 0 0
Argentina
State/province [21] 0 0
Ciudad Autonoma de Buenos Aire
Country [22] 0 0
Argentina
State/province [22] 0 0
Ciudad Autónoma de Buenos Aire
Country [23] 0 0
Argentina
State/province [23] 0 0
Córdoba
Country [24] 0 0
Argentina
State/province [24] 0 0
Mendoza
Country [25] 0 0
Argentina
State/province [25] 0 0
Santiago del Estero
Country [26] 0 0
Bulgaria
State/province [26] 0 0
Ruse
Country [27] 0 0
Bulgaria
State/province [27] 0 0
Sofia
Country [28] 0 0
Bulgaria
State/province [28] 0 0
Varna
Country [29] 0 0
Canada
State/province [29] 0 0
British Columbia
Country [30] 0 0
Canada
State/province [30] 0 0
Ontario
Country [31] 0 0
Canada
State/province [31] 0 0
Quebec
Country [32] 0 0
Chile
State/province [32] 0 0
II Región
Country [33] 0 0
Chile
State/province [33] 0 0
Region Metropolitana
Country [34] 0 0
Chile
State/province [34] 0 0
Región Metropolitana
Country [35] 0 0
Croatia
State/province [35] 0 0
Zagreb
Country [36] 0 0
Czechia
State/province [36] 0 0
Praha 10
Country [37] 0 0
Czechia
State/province [37] 0 0
Praha 2
Country [38] 0 0
Czechia
State/province [38] 0 0
Praha 6
Country [39] 0 0
Czechia
State/province [39] 0 0
Praha
Country [40] 0 0
Czechia
State/province [40] 0 0
Rychnov nad Kneznou
Country [41] 0 0
France
State/province [41] 0 0
Lille Cedex
Country [42] 0 0
France
State/province [42] 0 0
Marseille Cedex 5
Country [43] 0 0
France
State/province [43] 0 0
Paris Cedex
Country [44] 0 0
France
State/province [44] 0 0
Villeurbanne
Country [45] 0 0
Germany
State/province [45] 0 0
Bad Homburg
Country [46] 0 0
Germany
State/province [46] 0 0
Berlin
Country [47] 0 0
Germany
State/province [47] 0 0
Cologne
Country [48] 0 0
Germany
State/province [48] 0 0
Ellwangen
Country [49] 0 0
Germany
State/province [49] 0 0
Leipzig
Country [50] 0 0
Germany
State/province [50] 0 0
Mannheim
Country [51] 0 0
Germany
State/province [51] 0 0
Munchen
Country [52] 0 0
Germany
State/province [52] 0 0
Nürnberg
Country [53] 0 0
Germany
State/province [53] 0 0
Ulm
Country [54] 0 0
Germany
State/province [54] 0 0
Westerstede
Country [55] 0 0
Italy
State/province [55] 0 0
Brescia
Country [56] 0 0
Italy
State/province [56] 0 0
Cefalu
Country [57] 0 0
Italy
State/province [57] 0 0
Pavia
Country [58] 0 0
Italy
State/province [58] 0 0
Perugia
Country [59] 0 0
Italy
State/province [59] 0 0
Roma
Country [60] 0 0
Italy
State/province [60] 0 0
Rome
Country [61] 0 0
Italy
State/province [61] 0 0
Torino
Country [62] 0 0
Korea, Republic of
State/province [62] 0 0
Busan
Country [63] 0 0
Korea, Republic of
State/province [63] 0 0
Seoul
Country [64] 0 0
Poland
State/province [64] 0 0
Bialystok
Country [65] 0 0
Poland
State/province [65] 0 0
Bydgoszcz
Country [66] 0 0
Poland
State/province [66] 0 0
Katowice
Country [67] 0 0
Poland
State/province [67] 0 0
Poznan
Country [68] 0 0
Poland
State/province [68] 0 0
Szczecin
Country [69] 0 0
Poland
State/province [69] 0 0
Warszawa
Country [70] 0 0
Serbia
State/province [70] 0 0
Belgrade
Country [71] 0 0
Serbia
State/province [71] 0 0
Kragujevac
Country [72] 0 0
Serbia
State/province [72] 0 0
Novi Kneževac
Country [73] 0 0
Serbia
State/province [73] 0 0
Vršac
Country [74] 0 0
Singapore
State/province [74] 0 0
Singapore
Country [75] 0 0
Slovakia
State/province [75] 0 0
Banska Bystrica
Country [76] 0 0
Slovakia
State/province [76] 0 0
Dubnica nad Vahom
Country [77] 0 0
Slovakia
State/province [77] 0 0
Krompachy
Country [78] 0 0
Slovakia
State/province [78] 0 0
Svidník
Country [79] 0 0
Spain
State/province [79] 0 0
Alicante
Country [80] 0 0
Spain
State/province [80] 0 0
Barcelona
Country [81] 0 0
Spain
State/province [81] 0 0
Getxo
Country [82] 0 0
Spain
State/province [82] 0 0
San Sebastián
Country [83] 0 0
Taiwan
State/province [83] 0 0
Taoyuan
Country [84] 0 0
United Kingdom
State/province [84] 0 0
Bath
Country [85] 0 0
United Kingdom
State/province [85] 0 0
Blackpool
Country [86] 0 0
United Kingdom
State/province [86] 0 0
Cambridge
Country [87] 0 0
United Kingdom
State/province [87] 0 0
Carnoch
Country [88] 0 0
United Kingdom
State/province [88] 0 0
Epping
Country [89] 0 0
United Kingdom
State/province [89] 0 0
Guildford
Country [90] 0 0
United Kingdom
State/province [90] 0 0
Leeds
Country [91] 0 0
United Kingdom
State/province [91] 0 0
London
Country [92] 0 0
United Kingdom
State/province [92] 0 0
Manchester
Country [93] 0 0
United Kingdom
State/province [93] 0 0
Oxford
Country [94] 0 0
United Kingdom
State/province [94] 0 0
Plymouth
Country [95] 0 0
United Kingdom
State/province [95] 0 0
Sheffield
Country [96] 0 0
United Kingdom
State/province [96] 0 0
Southampton
Country [97] 0 0
United Kingdom
State/province [97] 0 0
Swindon
Country [98] 0 0
United Kingdom
State/province [98] 0 0
Warrington

Funding & Sponsors
Primary sponsor type
Commercial sector/industry
Name
Axovant Sciences Ltd.
Address
Country

Ethics approval
Ethics application status

Summary
Brief summary
This 12-month open-label study will provide further information regarding the long-term safety and tolerability of intepirdine (RVT-101) for subjects with Alzheimer's disease who have completed the double-blind, placebo-controlled, lead-in study RVT-101-3001 (double-blind study).
Trial website
https://clinicaltrials.gov/study/NCT02586909
Trial related presentations / publications
Public notes

Contacts
Principal investigator
Name 0 0
Ilise Lombardo, MD
Address 0 0
Axovant Sciences, Inc., Vice President, Clinical Research
Country 0 0
Phone 0 0
Fax 0 0
Email 0 0
Contact person for public queries
Name 0 0
Address 0 0
Country 0 0
Phone 0 0
Fax 0 0
Email 0 0
Contact person for scientific queries



Summary Results

For IPD and results data, please see https://clinicaltrials.gov/study/NCT02586909